COM 1 & 2 studies

In MF, a JAK2 mutation leads to _____________ of the JAK/STAT pathway and the abnormal production of blood cells

JAKAVI blocks the __________ stimulation of the JAK/STAT signalling pathway, thereby regulating the activation of genes that promote cell survival and proliferation.

JAKAVI is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. TRUE or FALSE

• TRUE

• FALSE

Dysregulated JAK/STAT signalling causes ___________ of blood cells in PV.

Patients treated with JAKAVI showed an improvement in splenomegaly, symptom score, and reduced risk of death compared with BAT.

• COMFORT 1

• COMFORT 2

• Both COMFORT 1 & 2

Patients treated with JAKAVI showed an improvement in splenomegaly and symptoms score as well as reduced risk of death compared with placebo.

• COMFORT 1

• COMFORT 2

• Both COMFORT 1 & 2

JAKAVI is indicated for the treatment of disease-related splenomegaly or symptoms in

adult patients with

• PMF

• Post - PV MF

• Post-ET MF

• All of the Options stated

• None of the Options staed

Intermediate-2 or high-risk MF

Resistant or refractory to or intolerant of available treatment

Splenomegaly.

• COMFORT 1

• COMFORT 2

• BOTH COMFORT 1 & 2

PRIMARY ENDPOINT: Proportion of patients achieving a ≥35% reduction in spleen volume from baseline at Week 24.

• COMFORT 1

• COMFORT 2

• BOTH COMFORT 1 & 2

Primary endpoint: Proportion of patients achieving a ≥35% reduction in spleen volume from baseline at Week 48 (as measured by MRI or CT scan)

Primary study with long-term extension

• COMFORT 1

• COMFORT 2

• BOTH COMFORT 1 & 2